NEW YORK, NY / ACCESSWIRE / October 3, 2022 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Azure Power Global Limited (NYSE:AZRE)

Class Period: June 15, 2021 - August 26, 2022

Deadline: October 31, 2022
For more info:www.bgandg.com/azre.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the complaint alleges that Defendants failed to disclose to investors that: (1) there were procedural irregularities, including deviations from safety and quality standards, at one of Azure's plants; (2) certain project data was manipulated; (3) as a result of the foregoing, the Company's internal controls and procedures were not effective; (4) Azure had received a credible whistleblower report alleging such misconduct; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Abbott Laboratories (NYSE:ABT)

Class Period: February 19, 2021 - June 8, 2022

Deadline: October 31, 2022
For more info:www.bgandg.com/abt.

The complaint alleges that, throughout the Class Period, Defendants made numerous materially false and misleading statements and omissions concerning what the U.S. Food and Drug Administration ('FDA') called 'egregiously unsanitary' conditions at the Company's Sturgis facility. Specifically, the complaint alleges that Defendants repeatedly touted to investors the safety and salability of Abbott's infant formula brands and their contribution to the Company's sales and revenue growth.

Latch, Inc. f/k/a TS Innovation Acquisitions Corp.

(NASDAQ:LTCH, LTCHW, TSIA, TSIAW, TSIAU)

Class Period: May 13, 2021 - August 25, 2022

Deadline: October 31, 2022
For more info:www.bgandg.com/ltch.

The Complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, defendants failed to disclose to investors that: (1) there were unreported sales arrangements related to hardware devices; (2) as a result, the Company had improperly recognized revenue throughout fiscal 2021 and first quarter 2022; (3) there were material weaknesses in Latch's internal control over financial reporting related to revenue recognition; (4) as a result of the foregoing, Latch would restate financial statements for fiscal 2021 and first quarter 2022; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | [email protected]

SOURCE: Bronstein, Gewirtz & Grossman, LLC